Platelet-activating factor is a renal vasodilator in the anesthetized rat.
In view of the potent vasoactive properties of platelet-activating factor (PAF), we investigated the renal hemodynamic effects of this lipid. C16-PAF (0.5-10 ng/kg) given as a bolus into the renal arterial circulation of pentobarbital sodium-anesthetized male Wistar rats produced a dose-dependent increase in renal blood flow (6-15%), before causing systemic hypotension. The PAF-induced renal vasodilation and systemic hypotension was independent of renal innervation, unaltered by eicosanoid synthesis inhibition with indomethacin or dexamethasone, unchanged by the nonselective dopamine-receptor antagonist haloperidol, but was abolished by the PAF-receptor antagonist, L-659,989. Non-hypotensive intrarenal PAF infusion at 0.5 ng.min-1.kg-1 caused an increase in renal blood flow. Thus PAF can cause renal vasodilation in the rat kidney that is PAF-receptor mediated and does not involve the sympathetic nervous system or the release of vasodilatory arachidonic acid metabolites or dopamine.
Handa
R K
RK
Department of Medicine/Nephrology, Bowman Gray School of Medicine, Wake Forest University, Winston-Salem, North Carolina 27103.
Strandhoy
J W
JW
Buckalew
V M
VM
D000758:Anesthesia; D000818:Animals; D015777:Eicosanoids / Q000037:antagonists & inhibitors; D006220:Haloperidol / Q000494:pharmacology; D007213:Indomethacin / Q000494:pharmacology; D008297:Male; D010972:Platelet Activating Factor / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains; D011954:Receptors, Dopamine / Q000187:drug effects; D012079:Renal Circulation / Q000187:drug effects*; D014665:Vasodilator Agents / Q000494:pharmacology*
D015777:Eicosanoids; D010972:Platelet Activating Factor; D011954:Receptors, Dopamine; D014665:Vasodilator Agents; D006220:Haloperidol; D007213:Indomethacin